Medicare GLP-1 Bridge Program — The Provider's Guide

A complete provider guide to the Medicare GLP-1 Bridge Program starting July 1, 2026 — clinical qualifications, covered medications, prior authorization, patient cost, and what it means for your practice.

By AJ Pakpour — The Business of Modern Medicine™

Educational Summary

The Medicare GLP-1 Bridge Program is a temporary CMS Demonstration Program running from July 1, 2026 through December 31, 2027. It makes FDA-approved weight management medications — Foundayo® (tablet), Wegovy® (injection or tablet), and Zepbound® KwikPen — more accessible and affordable for eligible Medicare beneficiaries at a flat $50/month patient cost.

This program is a direct response to the growing obesity and metabolic disease crisis in the Medicare population. CMS designed it as a bridge to expand access while longer-term coverage policy is finalized. For providers, it represents a significant clinical and practice opportunity — patients who previously couldn't afford GLP-1 therapy now have a clear, low-cost pathway.

**Who Is Eligible?** Patients must be 18+ and meet one of three BMI-based clinical thresholds at the time of GLP-1 therapy initiation: BMI ≥ 35 (no additional comorbidity required); BMI ≥ 30 with at least one qualifying condition (HFpEF/Diastolic Heart Failure, Uncontrolled Hypertension, CKD Stage 3a or higher, Prediabetes, Previous MI/Stroke, or Symptomatic PAD); or BMI ≥ 27 with Prediabetes, Previous MI, Previous Stroke, or Symptomatic PAD.

**Covered Plan Types** The Bridge Program applies to Part D PDP (standalone plans), Medicare Advantage Drug Plans (HMO, HMO-POS, PPO), SNPs, EGWPs, and LI NET. Most Medicare beneficiaries with drug coverage are eligible.

**Patient Cost Structure** The $50/month copay does NOT count toward the Part D Deductible, TrOOP/OOP Max, LIS/Extra Help, or the Medicare Prescription Payment Plan. This is a meaningful distinction — it keeps the patient's out-of-pocket exposure predictable and low throughout the year.

**Who Is Excluded?** Patients already receiving GLP-1 coverage through Part D, or who have a Part D-coverable GLP-1 indication (Type 2 Diabetes, Moderate to Severe Obstructive Sleep Apnea, or MASH/Fatty Liver Disease), are NOT eligible for the Bridge Program. These patients should be routed through their standard Part D plan instead.

**Provider Requirements** Providers must send the prescription to the pharmacy, complete prior authorization when requested, and certify that the medication is for weight reduction/maintenance WITH ongoing lifestyle modification, structured nutrition, and physical activity. Importantly, the provider does NOT have to be enrolled in Medicare and cannot be on the Medicare Preclusion List.

**Prior Authorization** Once approved, PA is valid for refills and dose changes through December 31, 2027 — unless the patient changes to a different GLP-1 medication. This reduces administrative burden significantly compared to annual PA renewals.

**Labs & Monitoring** CMS does not list required labs for Bridge approval, but for clinical risk management, providers should document baseline and follow-up data including Weight/BMI/Vitals, Medication History, A1c, CMP (renal/hepatic), Lipid Panel, Thyroid History (as indicated), Nutrition & Exercise Plan, and Ongoing Monitoring.

**Treatment Duration** There is no set limit on months of therapy during the demonstration period. Treatment continues based on clinical judgment, patient response, tolerability, and ongoing program eligibility. All FDA-approved dose titrations are included.

Key Takeaways

• ✓Program runs July 1, 2026 – December 31, 2027 as a temporary CMS Demonstration Program
• ✓Covered medications: Foundayo® (tablet), Wegovy® (injection or tablet), Zepbound® KwikPen only
• ✓Patient cost is $50/month — does NOT count toward Part D deductible, TrOOP, or OOP max
• ✓Three BMI-based eligibility tiers: BMI ≥ 35, BMI ≥ 30 + comorbidity, or BMI ≥ 27 + specific conditions
• ✓Patients with T2D, Sleep Apnea, or MASH/Fatty Liver Disease are excluded — route through Part D instead
• ✓Prior authorization is valid through 12/31/2027 for refills and dose changes
• ✓Provider does NOT need to be enrolled in Medicare to prescribe under this program
• ✓No set limit on treatment duration — continue based on clinical judgment through the demo period